We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+30.91%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.29B
AUM Growth
+$94.4M
Cap. Flow
-$78.5M
Cap. Flow %
-6.1%
Top 10 Hldgs %
48.93%
Holding
207
New
56
Increased
31
Reduced
35
Closed
51

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$30.6M
2
QURE icon
uniQure
QURE
+$18.4M
3
NVRO
NEVRO CORP.
NVRO
+$16.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$12.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$12M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$34.8M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$21.8M
3
ESPR
Esperion Therapeutics
ESPR
+$19.5M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$19.3M
5
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 84.11%
2 Miscellaneous 14.93%
3 Consumer Staples 0.85%
4 Technology 0.05%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARO
51
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$4.74M 0.37%
33,574
-120,454
-78% -$18.5M
NDRM
52
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.7M 0.37%
350,000
– –
LJPC
53
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.63M 0.36%
252,915
-36,040
-12% -$731K
ALDR
54
DELISTED
Alder Biopharmaceuticals
ALDR
$4.33M 0.34%
+150,000
New +$4.12M
THOR
55
CALL
DELISTED
THORATEC CORPORATION
THOR
$4.19M 0.33%
100,000
– –
ARDX icon
56
Ardelyx
ARDX
$878M
$4.14M 0.32%
315,955
+60,227
+24% +$1.13M
NERV icon
57
Minerva Neurosciences
NERV
$183M
$4.05M 0.31%
+101,317
New +$4.2M
ABEO icon
58
Abeona Therapeutics
ABEO
$313M
$3.92M 0.31%
50,000
– –
ASXC
59
DELISTED
Asensus Surgical, Inc.
ASXC
$3.89M 0.3%
102,205
-59,003
-37% -$2.23M
XENE icon
60
Xenon Pharmaceuticals
XENE
$5.45B
$3.79M 0.29%
225,000
– –
HCA icon
61
HCA Healthcare
HCA
$91.8B
$3.76M 0.29%
50,000
+1,361
+3% +$97.7K
TTPH
62
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.66M 0.28%
5,000
– –
ALDX icon
63
Aldeyra Therapeutics
ALDX
$82.6M
$3.63M 0.28%
+357,000
New +$3.64M
SAGE
64
DELISTED
Sage Therapeutics
SAGE
$3.54M 0.28%
70,484
– –
CELG
65
DELISTED
Celgene Corp
CELG
$3.46M 0.27%
29,967
-116,600
-80% -$13.9M
MGNX icon
66
MacroGenics
MGNX
$257M
$3.33M 0.26%
106,208
-109,607
-51% -$3.72M
TARA icon
67
Protara Therapeutics
TARA
$222M
$3.2M 0.25%
6,875
– –
PCYC
68
DELISTED
PHARMACYCLICS INC
PCYC
$3.07M 0.24%
+12,000
New +$2.32M
RDUS
69
DELISTED
Radius Health, Inc.
RDUS
$3.05M 0.24%
+74,000
New +$3.32M
RGEN icon
70
PUT
Repligen
RGEN
$9.86B
$3.04M 0.24%
100,000
– –
DSCI
71
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.91M 0.23%
343,284
+29,701
+9% +$253K
RPTP
72
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$2.87M 0.22%
+264,200
New +$2.7M
NVTA
73
DELISTED
Invitae Corporation
NVTA
$2.77M 0.21%
+165,000
New +$3.06M
IMMU
74
PUT
DELISTED
Immunomedics Inc
IMMU
$2.63M 0.2%
+600,000
New +$2.61M
CHRS icon
75
Coherus Oncology
CHRS
$205M
$2.61M 0.2%
85,288
-352,712
-81% -$9.12M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Perceptive Advisors held 207 positions worth $1.29B, up 7.9% from $1.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Perceptive Advisors withdrew a net $78.5M in Q1 2015, closing 51 positions and reducing 35 holdings. Its most notable exit was PTC Therapeutics, an estimated $34.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Iovance Biotherapeutics worth $32.9M.

  • Perceptive Advisors's largest Q1 2015 buy was Iovance Biotherapeutics: 2,714,549 shares worth $32.9M.
  • Perceptive Advisors added most to uniQure in Q1 2015, an estimated $18.4M increase.
  • Perceptive Advisors's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $21.8M.
  • Perceptive Advisors fully exited PTC Therapeutics in Q1 2015, selling an estimated $34.8M.
  • Perceptive Advisors's ten largest holdings make up 49% of its $1.29B portfolio in Q1 2015.
  • Perceptive Advisors opened 56 new positions and closed 51 in Q1 2015.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $1.29B.

Based on Perceptive Advisors's 13F filing for Q1 2015, filed 15 May 2015.